Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pfs25 + Pfs230
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Pfs25 + Pfs230** is a combination transmission-blocking vaccine candidate targeting Plasmodium falciparum sexual stage antigens to prevent malaria transmission from humans to mosquitoes. Pfs25, expressed on zygotes and ookinetes post-fertilization, and Pfs230 (or its domain 1, Pfs230D1), a prefertilization gamete surface protein involved in male microgamete fertilization of female macrogametes, are conjugated to carrier protein ExoProtein A (EPA) and formulated in Alhydrogel adjuvant. In clinical trials, the combination was safe and well-tolerated but did not improve functional transmission-reducing activity (TRA) over Pfs230D1 alone, which outperformed Pfs25 alone in humans due to complement-dependent enhancement; preclinical studies in mice showed similar activity for both antigens.[1][5]
- Other names
- Pfs25/Pfs230D1 combinationPfs25 + Pfs230D1
02
Targets
Pfs230Pfs25
Beyond the preview
Go deeper on Pfs25 + Pfs230.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pfs25 + Pfs230.